Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.
Cronos Group Inc. (CRON) generates frequent news as a cannabinoid-focused company active in medical and adult-use cannabis markets across Canada, Israel and multiple international regions. Company updates often highlight brand performance, international expansion, product launches and financial results, offering investors and industry observers insight into how Cronos executes its global cannabis strategy.
News coverage for Cronos commonly includes quarterly earnings releases, where the company reports net revenue, gross profit, adjusted EBITDA and commentary on business performance by geography and brand. These releases also describe developments such as the consolidation and expansion of cultivation operations at Cronos Growing Company Inc. (Cronos GrowCo) and the company’s cash and short-term investment position.
Another major category of Cronos news involves brand and product announcements. Recent press releases describe new SOURZ by Spinach® Fully Blasted multipack gummies, seasonal Spinach® Caramel Green Apple gummies and vapes, and Lord Jones® Live Resin Fusions™ pre-rolls in Canada. These updates show how Cronos uses its Spinach® and Lord Jones® brands to introduce new formats and flavor profiles in the Canadian adult-use market.
Cronos also issues news on its international footprint and strategic transactions. Examples include the expansion of PEACE NATURALS® medical cannabis distribution in Switzerland through a partnership with Dascoli Pharma AG, and a definitive agreement for a Cronos subsidiary to acquire CanAdelaar B.V., a licensed producer in the Netherlands’ adult-use cannabis pilot program. In addition, the company has announced a junior secured convertible loan investment in High Tide Inc., a cannabis retailer, outlining the terms of that financing.
Investors and followers of CRON can use this news feed to review earnings announcements, track new product introductions under Spinach®, PEACE NATURALS® and Lord Jones®, and monitor strategic moves such as international partnerships, acquisitions and capital investments.
Cronos Group Inc. (NASDAQ: CRON), a global cannabinoid company, appointed Bob Madore as Chief Financial Officer, effective August 9, 2021. He succeeds Jerry Barbato, whose contributions in finance and procurement were acknowledged. Bob has a 30-year financial leadership background, previously serving as CFO at American Eagle Outfitters and Ralph Lauren. His role is expected to enhance Cronos's growth opportunities and shareholder value. The announcement coincided with the release of the Company's second-quarter financial results, marking a significant leadership transition at Cronos Group.
Cronos Group Inc. reported its 2021 Q2 results, highlighting a consolidated net revenue of $15.6 million, a 58% increase year-over-year. Significant growth was driven by the Canadian adult-use cannabis market, particularly the Spinach™ brand. However, the company faced a gross loss of $15.8 million, attributed to inventory write-downs and start-up costs. A strategic investment in PharmaCann aims to bolster U.S. market presence. The company launched new products, including SOURZ by Spinach™ gummies, and amended its agreement with Ginkgo Bioworks to enhance cannabinoid production.
Cronos Group has launched SOURZ by Spinach™ gummies, a new line of cannabis edibles designed for adult consumers. The gummies feature bold dual flavors and proprietary flavor masking technology, enhancing the taste experience. Each gummy contains 2 mg of THC, available in flavors like Peach Orange and Blue Raspberry Watermelon. A recent survey indicated that 46% of Canadian cannabis users favor gummies over other edibles. Cronos aims to innovate in the growing edibles market, enhancing consumer experiences as pandemic restrictions ease across Canada.
Cronos Group Inc. (NASDAQ: CRON) will host its 2021 Second Quarter Earnings Conference Call on August 6, 2021, at 8:30 a.m. EDT. Senior management will review the Company’s financial results and address questions from investors. A live audio webcast will be accessible on the Company’s website, and the call will be archived for later listening. Cronos Group focuses on developing cannabinoid products globally, with brands like PEACE NATURALS™, COVE™, and Spinach™ in its portfolio.
Cronos Group held its Annual Meeting of Shareholders on June 25, 2021, with 75.35% of outstanding shares represented. All proposed directors were elected, receiving over 94.38% of votes. Notable votes included Kendrick Ashton, Jr. with 99.61% support and Jody Begley with 94.38%. An advisory resolution on executive compensation was approved by 93.64% of votes. KPMG LLP was re-appointed as independent auditors. For complete voting results, refer to the Company’s filings on SEDAR and EDGAR.
Cronos Group has entered into a strategic agreement to purchase an option for a 10.5% stake in PharmaCann for approximately $110.4 million. This investment positions Cronos to benefit from the expanding U.S. cannabis market, particularly in states where PharmaCann operates, which includes six limited-license states. Both companies plan to collaborate on product distribution and governance rights following the option's exercise, contingent on regulatory approvals and U.S. federal cannabis legalization.
Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks have amended their collaboration agreement to expedite the commercialization of cultured cannabinoids. The new terms allow Cronos to market products using cultured cannabinoids before meeting previously defined productivity targets, enhancing their market position in Canada. Following the receipt of necessary licenses, Cronos has commenced commercial production of CBG. The agreement maintains the original share issuance structure tied to productivity milestones, with the potential to produce rare cannabinoids reliably and economically.
Cronos Group, a global cannabinoid company, announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11, 2021, at 2:30 p.m. EDT. Participants can access the live webcast at thecronosgroup.com. Following the event, a replay will be available. Cronos is focused on developing disruptive intellectual property and building a strong brand portfolio with products like PEACE NATURALS, COVE, and Spinach.
Cronos Group (NASDAQ: CRON) has unveiled a comprehensive Marketing Code aimed at promoting responsible marketing practices in the cannabis industry. This initiative emphasizes that marketing should not target individuals below the legal consumption age. The code will govern all Cronos marketing activities worldwide and is intended to engage both industry peers and policymakers. Key principles include adult-targeted advertising, responsible consumption messaging, and transparency in claims. Cronos Group's leadership believes this initiative is vital for fostering trust in the evolving cannabis market.
Cronos Group recently announced its Q1 2021 results, reporting consolidated net revenue of $12.6 million, a 50% increase from Q1 2020, driven by growth in the Canadian and Israeli markets. Despite increased sales, the company experienced a gross loss of $2.96 million, improved from $6.48 million a year prior. The newly acquired processing license for cannabinoid biosynthesis is a significant achievement, supporting innovative product development. However, adjusted EBITDA loss slightly increased to $37.1 million, reflecting higher marketing and R&D costs.